How Should We Treat Pancreatic Metastases from Renal Cell Carcinoma? A Meta-Analysis.
Journal
World journal of surgery
ISSN: 1432-2323
Titre abrégé: World J Surg
Pays: United States
ID NLM: 7704052
Informations de publication
Date de publication:
07 2021
07 2021
Historique:
accepted:
06
03
2021
pubmed:
27
3
2021
medline:
29
6
2021
entrez:
26
3
2021
Statut:
ppublish
Résumé
The treatment strategy for pancreatic metastasis (PM) from renal cell carcinoma (RCC) is unclear due to its rarity. The aim of this study was to reveal the role of surgery for PM from RCC. A systematic literature search was conducted using PubMed and the Cochrane Library. The effectiveness of surgery for PM was evaluated based on the primary outcome of overall survival (OS), which was investigated in relation to surgical procedures and metastatic sites via subgroup analyses. There was no significant difference in the rate of 2-year OS between the surgery and control group (OR 0.43, 95% CI 0.14-1.26, P = 0.12). However, the rate of 5-year OS was significantly higher in the surgery group than the control group (OR = 0.41, 95% CI 0.18-0.93, P = 0.03). The rates of the complications and OS were not significantly different between radical and conservative pancreatectomies. The rate of 5-year OS of the patients with PM was higher than that with other metastases (OR 0.38, 95% CI 0.20-0.74, P = 0.004). Surgical resection for PM from RCC is associated with good prognosis. Limited surgery may be a useful option depending on the location of the lesion.
Sections du résumé
BACKGROUND
The treatment strategy for pancreatic metastasis (PM) from renal cell carcinoma (RCC) is unclear due to its rarity. The aim of this study was to reveal the role of surgery for PM from RCC.
METHODS
A systematic literature search was conducted using PubMed and the Cochrane Library. The effectiveness of surgery for PM was evaluated based on the primary outcome of overall survival (OS), which was investigated in relation to surgical procedures and metastatic sites via subgroup analyses.
RESULTS
There was no significant difference in the rate of 2-year OS between the surgery and control group (OR 0.43, 95% CI 0.14-1.26, P = 0.12). However, the rate of 5-year OS was significantly higher in the surgery group than the control group (OR = 0.41, 95% CI 0.18-0.93, P = 0.03). The rates of the complications and OS were not significantly different between radical and conservative pancreatectomies. The rate of 5-year OS of the patients with PM was higher than that with other metastases (OR 0.38, 95% CI 0.20-0.74, P = 0.004).
CONCLUSION
Surgical resection for PM from RCC is associated with good prognosis. Limited surgery may be a useful option depending on the location of the lesion.
Identifiants
pubmed: 33768307
doi: 10.1007/s00268-021-06071-x
pii: 10.1007/s00268-021-06071-x
doi:
Types de publication
Journal Article
Meta-Analysis
Langues
eng
Sous-ensembles de citation
IM
Pagination
2191-2199Références
Adsay NV, Andea A, Basturk O, Kilinc N, Nassar H, Cheng JD (2004) Secondary tumors of the pancreas: an analysis of a surgical and autopsy database and review of the literature. Virchows Arch 444:527–535
doi: 10.1007/s00428-004-0987-3
Niess H, Conrad C, Kleespies A et al (2013) Surgery for metastasis to the pancreas: is it safe and effective? J Surg Oncol 107:859–864
doi: 10.1002/jso.23333
Grassi P, Doucet L, Giglione P et al (2016) Clinical impact of pancreatic metastases from renal cell carcinoma: a multicenter retrospective analysis. PLoS ONE 11:e0151662
doi: 10.1371/journal.pone.0151662
Sohn TA, Yeo CJ, Cameron JL et al (2001) Renal cell carcinoma metastatic to the pancreas: results of surgical management. J Gastrointest Surg 5:346–351
doi: 10.1016/S1091-255X(01)80060-3
Xue J, Chen W, Xu W et al (2021) Patterns of distant metastases in patients with clear cell renal cell carcinoma—a population-based analysis. Cancer Med 10:173–187
doi: 10.1002/cam4.3596
Ballarin R, Spaggiari M, Cautero N et al (2011) Pancreatic metastases from renal cell carcinoma: the state of the art. World J Gastroenterol 17:4747–4756
doi: 10.3748/wjg.v17.i43.4747
Santoni M, Conti A, Porta C et al (2015) Sunitinib, pazopanib or sorafenib for the treatment of patients with late relapsing metastatic renal cell carcinoma. J Urol 193:41–47
doi: 10.1016/j.juro.2014.07.011
Berquist SW, Yim K, Ryan ST et al (2019) Systemic therapy in the management of localized and locally advanced renal cell carcinoma: current state and future perspectives. Int J Urol 26:532–542
doi: 10.1111/iju.13943
Adashek JJ, Genovese G, Tannir NM et al (2020) Recent advancements in the treatment of metastatic clear cell renal cell carcinoma: a review of the evidence using second-generation p-values. Cancer Treat Res Commun 23:100166
doi: 10.1016/j.ctarc.2020.100166
Tanis PJ, van der Gaag NA, Busch OR et al (2009) Systematic review of pancreatic surgery for metastatic renal cell carcinoma. Br J Surg 96:579–592
doi: 10.1002/bjs.6606
Masetti M, Zanini N, Martuzzi F et al (2010) Analysis of prognostic factors in metastatic tumors of the pancreas: a single-center experience and review of the literature. Pancreas 39:135–143
doi: 10.1097/MPA.0b013e3181bae9b3
Yazbek T, Gayet B (2012) The place of enucleation and enucleo-resection in the treatment of pancreatic metastasis of renal cell carcinoma. JOP 13:433–438
pubmed: 22797401
Moher D, Liberati A, Tetzlaff J et al (2010) Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. Int J Surg 8:336–341
doi: 10.1016/j.ijsu.2010.02.007
Stang A (2010) Critical evaluation of the Newcastle-Ottawa scale for the assessment of the quality of nonrandomized studies in meta-analyses. Eur J Epidemiol 25:603–605
doi: 10.1007/s10654-010-9491-z
Mantel N, Haenszel W (1959) Statistical aspects of the analysis of data from retrospective studies of disease. J Natl Cancer Inst 22:719–748
pubmed: 13655060
Parmar MK, Torri V, Stewart L (1998) Extracting summary statistics to perform meta-analyses of the published literature for survival endpoints. Stat Med 17:2815–2834
doi: 10.1002/(SICI)1097-0258(19981230)17:24<2815::AID-SIM110>3.0.CO;2-8
Ghavamian R, Klein KA, Stephens DH et al (2000) Renal cell carcinoma metastatic to the pancreas: clinical and radiological features. Mayo Clin Proc 75:581–585
doi: 10.4065/75.6.581
Bassi C, Butturini G, Falconi M et al (2003) High recurrence rate after atypical resection for pancreatic metastases from renal cell carcinoma. Br J Surg 90:555–559
doi: 10.1002/bjs.4072
Moussa A, Mitry E, Hammel P et al (2004) Pancreatic metastases: a multicentric study of 22 patients. Gastroenterol Clin Biol 28:872–876
doi: 10.1016/S0399-8320(04)95151-2
Zerbi A, Ortolano E, Balzano G et al (2008) Pancreatic metastasis from renal cell carcinoma: which patients benefit from surgical resection? Ann Surg Oncol 15:1161–1168
doi: 10.1245/s10434-007-9782-0
Moletta L, Milanetto AC, Vincenzi V et al (2014) Pancreatic secondary lesions from renal cell carcinoma. World J Surg 38:3002–3006. https://doi.org/10.1007/s00268-014-2672-2
doi: 10.1007/s00268-014-2672-2
pubmed: 24962493
Chang YH, Liaw CC, Chuang CK (2015) The role of surgery in renal cell carcinoma with pancreatic metastasis. Biomed J 38:173–176
doi: 10.4103/2319-4170.137771
Santoni M, Conti A, Partelli S et al (2015) Surgical resection does not improve survival in patients with renal metastases to the pancreas in the era of tyrosine kinase inhibitors. Ann Surg Oncol 22:2094–2100
doi: 10.1245/s10434-014-4256-7
You DD, Choi DW, Choi SH et al (2011) Surgical resection of metastasis to the pancreas. J Kor Surg Soc 80:278–282
doi: 10.4174/jkss.2011.80.4.278
Grassi P, Verzoni E, Mariani L et al (2013) Prognostic role of pancreatic metastases from renal cell carcinoma: results from an Italian center. Clin Genitourin Cancer 11:484–488
doi: 10.1016/j.clgc.2013.04.022
Kalra S, Atkinson BJ, Matrana MR et al (2016) Prognosis of patients with metastatic renal cell carcinoma and pancreatic metastases. BJU Int 117:761–765
doi: 10.1111/bju.13185
Chrom P, Stec R, Bodnar L et al (2018) Prognostic significance of pancreatic metastases from renal cell carcinoma in patients treated with tyrosine kinase inhibitors. Anticancer Res 38:359–365
pubmed: 29277795
Dong J, Cong L, Zhang TP et al (2016) Pancreatic metastasis of renal cell carcinoma. Hepatobiliary Pancreat Dis Int 15:30–38
doi: 10.1016/S1499-3872(16)60052-8
Motzer RJ, Mazumdar M, Bacik J et al (1999) Survival and prognostic stratification of 670 patients with advanced renal cell carcinoma. J Clin Oncol 17:2530–2540
doi: 10.1200/JCO.1999.17.8.2530
Mekhail TM, Abou-Jawde RM, Boumerhi G et al (2005) Validation and extension of the Memorial Sloan-Kettering prognostic factors model for survival in patients with previously untreated metastatic renal cell carcinoma. J Clin Oncol 23:832–841
doi: 10.1200/JCO.2005.05.179
Bruchbacher A, Lemberger U, Hassler MR et al (2020) PD1/PD-L1 therapy in metastatic renal cell carcinoma. Curr Opin Urol 30:534–541
doi: 10.1097/MOU.0000000000000788
National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology: Kidney Cancer, version 1.2021.